NASDAQ:XBIT

XBiotech (XBIT) News Today

$4.36

-0.20 (-4.39%)

(As of 09/22/2023 ET)

Compare

Today's Range: $4.36
▼
$4.56
50-Day Range: $4.36
▼
$5.81
52-Week Range: $3.00
▼
$6.69

Volume: 7,375 shs
Average Volume: 21,352 shs
Market Capitalization: $132.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Source

Source	Headline
	XBiotech (NASDAQ:XBIT) Now Covered by Analysts at StockNews.com marketbeat.com - August 17 at 1:45 AM
	XBiotech Inc.: XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial finanznachrichten.de - August 8 at 12:23 PM
	XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial finance.yahoo.com - August 8 at 12:23 PM
	XBiotech Cancer Drug Survival Claim Falls Apart Under Scrutiny thestreet.com - June 30 at 8:58 AM
	StockNews.com Initiates Coverage on XBiotech (NASDAQ:XBIT) marketbeat.com - June 2 at 1:27 AM
	XBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients finanznachrichten.de - May 23 at 8:48 PM
	FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients finance.yahoo.com - May 22 at 1:26 PM
	XBiotech Inc.: XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares finanznachrichten.de - May 17 at 9:50 AM
	XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares finance.yahoo.com - May 17 at 9:50 AM
	XBiotech (NASDAQ:XBIT) Research Coverage Started at StockNews.com marketbeat.com - May 9 at 1:37 AM
	XBiotech (NASDAQ:XBIT) Receives New Coverage from Analysts at StockNews.com marketbeat.com - April 23 at 1:18 AM
	XBiotech Inc.: XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke finanznachrichten.de - April 17 at 2:39 PM
	XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke finance.yahoo.com - April 17 at 9:38 AM
	XBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insiders finance.yahoo.com - April 9 at 12:31 PM
	XBiotech (NASDAQ:XBIT) Earns Hold Rating from Analysts at StockNews.com marketbeat.com - April 4 at 1:25 AM
	The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitable finance.yahoo.com - February 15 at 10:06 AM
	XBiotech (NASDAQ:XBIT) Cut to Sell at StockNews.com marketbeat.com - November 15 at 3:13 AM
	Short Interest in XBiotech Inc. (NASDAQ:XBIT) Grows By 42.4% marketbeat.com - November 12 at 6:48 AM
	XBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021) finance.yahoo.com - November 11 at 7:50 AM
	Insiders own 35% of XBiotech Inc. (NASDAQ:XBIT) shares but individual investors control 47% of the company finance.yahoo.com - October 31 at 12:05 PM
	Helicobacter pylori Infection Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (2022-2032) \| DelveInsight - PR Newswire prnewswire.com - October 18 at 4:21 PM
	XBiotech (NASDAQ:XBIT) Lowered to "Sell" at StockNews.com marketbeat.com - October 18 at 2:17 AM
	XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer - Yahoo Finance finance.yahoo.com - October 13 at 5:53 PM
	XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer - GlobeNewswire globenewswire.com - October 13 at 12:52 PM
	XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer finance.yahoo.com - October 13 at 12:52 PM
	XBiotech Inc. (NASDAQ:XBIT) Short Interest Down 22.2% in September marketbeat.com - September 29 at 3:58 AM
	XBiotech (NASDAQ:XBIT) shareholders have endured a 73% loss from investing in the stock a year ago finance.yahoo.com - September 8 at 10:50 AM
	StockNews.com Lowers XBiotech (NASDAQ:XBIT) to Sell marketbeat.com - September 2 at 11:08 PM
	We Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth - Nasdaq nasdaq.com - September 2 at 4:27 PM
	Short Interest in XBiotech Inc. (NASDAQ:XBIT) Increases By 89.5% marketbeat.com - August 26 at 2:42 AM
	We Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth - Yahoo Finance finance.yahoo.com - August 14 at 10:26 PM
	XBIOTECH INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) \| MarketScreener - Marketscreener.com marketscreener.com - August 10 at 12:56 PM
	XBiotech Inc. (NASDAQ:XBIT) Short Interest Down 21.0% in July marketbeat.com - August 2 at 1:16 AM
	JOHNSON & JOHNSON MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - Marketscreener.com marketscreener.com - July 29 at 5:41 PM
	The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Benzinga benzinga.com - June 21 at 10:31 AM
	XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study - GlobeNewswire globenewswire.com - June 20 at 11:48 AM
	Form 10-Q XBiotech Inc. For: Mar 31 - StreetInsider.com streetinsider.com - May 10 at 11:56 PM
	XBiotech Sponsored Study Titled 'Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthr - Benzinga benzinga.com - May 7 at 9:35 AM
	XBiotech Sponsored Study Titled 'Natrunix Versus Methotrexate in Rheumatoid Arthritis' Posted To Clinical - Benzinga benzinga.com - May 6 at 6:59 PM
	XBiotech Inc. (NASDAQ:XBIT) Short Interest Down 19.2% in April marketbeat.com - May 3 at 5:34 AM
	74 Biggest Movers From Yesterday By Benzinga - Investing.com UK uk.investing.com - April 29 at 11:19 AM
	Why Are XBiotech Shares Trading Higher Today - Benzinga - Benzinga benzinga.com - April 29 at 11:19 AM
	XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer - GlobeNewswire globenewswire.com - April 28 at 1:34 PM
	Johnson & Johnson (JNJ) Q1 2022 Earnings Call Transcript - The Motley Fool fool.com - April 19 at 6:35 PM
	Akerman Lands Ex-BCLP Tax Partner In Denver - Law360 law360.com - April 8 at 4:38 PM
	StockNews.com Begins Coverage on XBiotech (NASDAQ:XBIT) marketbeat.com - March 31 at 1:14 AM
	XBIOTECH INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION (form 10-K) - Marketscreener.com marketscreener.com - March 15 at 6:42 PM
	XBiotech (NASDAQ:XBIT) shareholders have endured a 48% loss from investing in the stock a year ago finance.yahoo.com - March 15 at 1:40 PM
	Basem Goueli is Recognized by Continental Who's - PRNewswire prnewswire.com - February 6 at 10:29 AM
	White House mobilizes 'war room' to boost Fed nominees as attacks pile up - Nasdaq nasdaq.com - February 3 at 4:26 AM

Get XBiotech News Delivered to You Automatically

XBIT Media Mentions By Week

XBIT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

XBIT
News Sentiment
▼
0.00

0.53
▲
Average
Medical
News Sentiment

XBIT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

XBIT Articles
This Week
▼
0

0
▲
XBIT Articles
Average Week

Get XBiotech News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:XBIT) was last updated on 9/23/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

XBiotech (XBIT) News Today

XBIT Media Mentions By Week

XBIT Media Sentiment

XBIT News Coverage

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info